创新药概念持续拉升 舒泰神10天涨近1.9倍 智通财经6月3日电，午后创新药概念涨势持续扩大，人气股舒泰神封20CM涨停，最近10个交易日涨近 1.9倍，此前九芝堂、万邦德、千红制药、昂利康、海南海药涨停，华纳制药、泰恩康、常山药业均创 历史新高。 ...

Group 1 - Hemophilia is a hereditary bleeding disorder with approximately 140,000 patients in China and an inhibitor occurrence rate of about 18% [1] - The global market for hemophilia with inhibitors is estimated to be around 27.7 billion yuan, with key drugs including recombinant VIIa, PCC, and emicizumab, projected sales for 2024 are 8.27 billion yuan, 12.81 billion yuan, and 36.68 billion yuan respectively [1] - The domestic market for hemophilia treatment is primarily dominated by PCC due to drug supply and accessibility issues [1] Group 2 - FXa bomitapase α is a new FIC with expected peak sales in the domestic market exceeding 2 billion yuan, showing superior hemostatic efficacy and safety compared to Novoseven and PCC [1] - BDB-001/STSA-1002 targets C5a and is a new molecule with global rights, aimed at treating multiple indications including AAV and ARDS, with ARDS having a high hospitalization mortality rate of 35%-45% [2] - The company anticipates revenues of 294 million yuan, 448 million yuan, and 1.096 billion yuan for 2025, 2026, and 2027 respectively, with a projected net profit of -76 million yuan, -56 million yuan, and 289 million yuan for the same years [2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The report highlights positive topline results from the clinical trial of STSA-1002 for ARDS, indicating a significant reduction in clinical relief time and mortality rates compared to the control group [6] - The application for the market approval of Bomitase α has been accepted, and the company has completed changes to its drug production license [6] - Revenue projections for 2025-2027 are estimated at 294 million, 448 million, and 1.096 billion respectively, with a forecasted net profit of -76 million, -56 million, and 289 million [6] Financial Performance Summary - Revenue for 2023 is reported at 364 million, with a projected decline to 294 million in 2025 before increasing to 1.096 billion by 2027 [5][8] - The net profit is expected to improve from -399 million in 2023 to a positive 289 million in 2027 [5][8] - The earnings per share (EPS) is projected to rise from -0.84 in 2023 to 0.61 in 2027 [5][8] Clinical Trial Results - The clinical trial for STSA-1002 showed that the low-dose and high-dose groups had risk ratios of 1.04 and 1.55 respectively, with a reduction in the time to clinical relief by 2 to 5 days [6] - The 28-day all-cause mortality rates were 26.67% for the low-dose group, 5.88% for the high-dose group, and 40% for the control group, indicating a significant reduction in mortality [6] Market and Regulatory Developments - The company has received acceptance for the market application of STSP-0601 (Bomitase α), which is a significant regulatory milestone [6] - The report emphasizes the importance of the drug production license changes, which allow for the contracted production of Bomitase α [6]

2、经公司董事会核实，截至本公告披露日，公司、控股股东和实际控制人 不存在关于本公司的应披露而未披露的重大事项，在股票异常波动期间不存在买 卖公司股票的行为。 3、公司关注到近期市场对国家药品监督管理局药品审评中心（NMPA）网 站信息公开栏目关于"拟优先审评品种公示"栏中公司控股子公司江苏贝捷泰生 物科技有限公司申请的"注射用 STSP-0601"相关信息关注度较高；该药品正处 于公示期内，公示截止日期为 2025 年 06 月 03 日，关于该药品公示期满后，后 续是否进入优先审评程序仍存在诸多不确定性。敬请广大投资者谨慎决策，注意 防范投资风险。 4、风险提示：公司多个在研项目属于创新型生物制品。创新生物医药具有 高科技、高风险、高附加值的特点，从研制、临床试验、报批到投产的周期长、 环节多，容易受到技术、审批、政策等诸多因素影响，面临临床试验进度可能不 如预期、临床试验结果可能不如预期、药品申请上市批准可能不如预期等诸多风 险，请广大投资者谨慎决策，注意投资风险。 证券代码：300204 证券简称：舒泰神 公告编号：2025-038 舒泰神（北京）生物制药股份有限公司 关于股票交易异常波动的公告 本公 ...

Group 1 - The company Shuyou Shen (300204) experienced a significant stock increase of 15.02% today, with a trading volume of 1.573 billion yuan and a turnover rate of 13.23% [1] - Post-market data indicates that four institutional special seats net bought 132 million yuan, while one institutional special seat net sold 21.3859 million yuan [1] - There is a revelation of dark pool fund flows, suggesting early signals of stock accumulation by major investors [1]

智通财经5月30日电，创新药概念股盘中持续走强，万邦德、康弘药业、千红制药、华森制药、哈三 联、联化科技、海南海药、华纳药厂、睿智医药等10余股涨停，舒泰神、科兴制药、冠昊生物等涨超 10%。 创新药概念股持续走高 万邦德等10余股涨停 ...

Market Overview - Uncertainty over tariff outlook suppresses rebound in US stocks, with major indices closing higher: Dow Jones up 0.28%, S&P 500 up 0.4%, and Nasdaq up 0.39% [1] - Nvidia shares rise over 3% post-earnings, while Best Buy falls over 7%, C3.ai surges nearly 21%, and Dell sees a post-market increase of over 5% [1] - Chinese concept stocks index rises over 1%, ending a seven-day decline, with notable gains in stocks like Aiyu Holdings up 7.81%, JD.com up 4.31%, and Xpeng up 3.98% [1] Corporate Actions - Huang Renxun plans to sell up to 6 million shares of Nvidia, valued at over $800 million, significantly exceeding previous sales [3] - Dell Technologies reports AI server orders exceeding expectations, with a bright revenue outlook [4] Domestic Developments - The Central Committee and State Council issue opinions to enhance the market-oriented allocation of resource and environmental factors, encouraging the expansion of pollutant discharge rights trading [5] - The launch of the Hongdao operating system marks a significant advancement in China's foundational software for intelligent robots, supporting the autonomy of domestic robot operating systems [5] Industry Insights - The Ministry of Commerce and other departments release key enterprises and projects for national cultural exports for 2025-2026 [6] - Zhejiang issues implementation opinions to promote the innovative development of intelligent computing cloud, aiming for a scale of 60 EFlops by 2027 [7] - The establishment of a pilot base for embodied intelligence by Yushun Technology and Hangzhou Data Group [9] Stock Market Trends - Recent analysis indicates a market recovery with major indices and stocks showing upward movement after a period of adjustment, with a focus on technology, finance, and new consumption sectors [11] - The feed industry sees price increases of 50-100 yuan per ton due to rising corn prices, with expectations of continued upward trends in corn prices [12] - The carbon neutrality initiative aims to establish a market-oriented trading system for carbon emissions, water usage, and pollutant discharge by 2027, enhancing market activity and price formation mechanisms [13] New Initiatives - Douyin Group establishes a short drama copyright center to enhance copyright management and support quality production [14] - Zhiyuan Robotics announces its humanoid robot has received multiple certifications, marking a significant achievement in safety and technology standards [15][16] Upcoming IPOs - Yingshi Innovation plans to issue shares on the Sci-Tech Innovation Board at a price of 47.27 yuan per share, requiring a minimum market value of 65,000 yuan for top-tier subscriptions [17] Company Announcements - Guangyang Co. terminates the acquisition of 100% equity in Yinjing Technology, leading to stock resumption [18] - Shuanglin Co. plans to raise no more than 1.5 billion yuan for the industrialization of roller screw and joint modules [18] - Yuntian Lifa's DeepEdge10 chip has achieved commercialization in robotics and servers [18]

Group 1 - The innovative drug sector in A-shares has shown a strong comeback, with multiple stocks experiencing significant price increases, including Shuyou Shen (20% increase) and Ruizhi Pharmaceutical (20% increase), indicating a bullish market sentiment [1] - The Hong Kong market also saw a rise, with WuXi AppTec increasing by 19.88% and several innovative drug ETFs in Hong Kong showing year-to-date gains exceeding 40%, outperforming similar products [1][2] - Analysts suggest that the domestic market is entering a concentrated listing period for innovative drugs, supported by comprehensive policy backing and improvements in commercial medical insurance, which are expected to enhance the commercialization process beyond market expectations [1][5] Group 2 - There is a noticeable divergence in the performance of various medical ETFs, with some experiencing significant inflows while others face substantial outflows, indicating mixed investor sentiment [2][3] - The top-performing innovative drug ETFs, such as ICBC Hong Kong Innovative Drug ETF and Huatai-PineBridge Hong Kong Innovative Drug ETF, have seen net inflows of 2.43 billion and 2.31 billion respectively, while the E Fund CSI 300 Healthcare ETF has recorded the highest net outflow of 2.5 billion [3] - The medical sector is expected to show its best performance in three years by mid-2025, driven by policy optimization and AI industry empowerment, with a clear trend of performance and valuation recovery anticipated in the second half of the year [3] Group 3 - The innovative drug sector has rebounded significantly after a period of decline, with innovative drug ETFs showing substantial weekly gains, particularly in the lead-up to the ASCO annual meeting, which has heightened industry interest [4] - The upcoming ASCO meeting is expected to showcase numerous original research results from Chinese pharmaceutical companies, indicating a shift towards international innovation in drug development [4][5] - Recent approvals of six domestic innovative drugs in May across critical treatment areas such as diabetes and tumors have injected strong momentum into the pharmaceutical industry [5]

舒泰神："注射用STSP-0601"药品后续是否进入优先审评程序仍存在诸多不确定性 智通财经5月29日电，舒泰神(300204.SZ)公告称，公司股票连续十个交易日收盘价格涨幅偏离值累计超 过100%，连续三十个交易日收盘价格涨幅偏离值累计超过200%，属于股票交易严重异常波动情况。公 司关注到近期市场对国家药品监督管理局药品审评中心（NMPA）网站信息公开栏目关于"拟优先审评 品种公示"栏中公司控股子公司江苏贝捷泰生物科技有限公司申请的"注射用STSP-0601"相关信息关注度 较高；该药品正处于公示期内，公示截止日期为2025年06月03日，关于该药品公示期满后，后续是否进 入优先审评程序仍存在诸多不确定性。 ...

证券代码：300204 证券简称：舒泰神 公告编号：2025-037 舒泰神（北京）生物制药股份有限公司 关于股票交易严重异常波动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1、舒泰神（北京）生物制药股份有限公司股票交易连续十个交易日（2025 年05月16日至2025年05月29日）收盘价格涨幅偏离值累计超过100%；连续三十 个交易日（2025年04月15日至2025年05月29日）收盘价格涨幅偏离值累计超过 200%；根据《深圳证券交易所交易规则》等相关规定，属于股票交易严重异常 波动的情况。 2、经公司董事会核实，截至本公告披露日，公司、控股股东和实际控制人 不存在关于本公司的应披露而未披露的重大事项，在股票异常波动期间不存在买 卖公司股票的行为。 3、公司关注到近期市场对国家药品监督管理局药品审评中心（NMPA）网 站信息公开栏目关于"拟优先审评品种公示"栏中公司控股子公司江苏贝捷泰生 物科技有限公司申请的"注射用 STSP-0601"相关信息关注度较高；该药品正处 于公示期内，公示截止日期为 2025 年 06 月 03 ...